Evaluation of the effect of Zinc Sulfate on pruritus in patients under hemodialysis

Evaluation of the effect of Zinc Sulfate on pruritus score in patients under hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138806082370N2

Enrollment

Registered

2010-09-14

Start date

2008-04-27

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pruritus in Hemodialysis Patients. End-stage renal disease

Interventions

Intervention 1: Tab Zinc Sulfate 220 mg BID. Intervention 2: Placebo BID.

Treatment - Drugs

Placebo

Tab Zinc Sulfate 220 mg BID

Placebo BID

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: - Being under maintenance hemodialysis for at least one month - Not being under other drug treatment for pruritus - Having pruritus for at least 8 wk - No sensitivity to Zinc Sulfate - Volunteer to participate Exclusion criteria: - Non compliance with drug - Renal transplantation before end of therapy - Hypoparathyroidism - Alkalin phosphatase elevation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Changes in Pruritus Score. Timepoint: Every 2 wk. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mojgan Mortazavi

Isfahan University of Medical Sciences

m_mortazavi@med.mui.ac.ir+98 31 1625 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026